Status:

RECRUITING

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

Lead Sponsor:

University Hospital, Ghent

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant che...

Detailed Description

Study Aim The aim of this study is to assess whether the combination of radiomics, diffusion-weighted magnetic resonance imaging (DW-MRI), and multi-omics profiling in liquid biopsies-both before and ...

Eligibility Criteria

Inclusion

  • Male or female patients, aged 18 years and above
  • Diagnosis of BR or LA PDAC according to NCCN guidelines (version 1.2020)
  • Histologic diagnosis of PDAC
  • No medical or anesthetic contra-indication for surgery
  • Able to understand nature of the study procedures
  • Willing to participate and give written informed consent

Exclusion

  • Age \< 18 years
  • Distant metastases
  • Histologic diagnosis of cholangiocarcinoma, duodenal carcinoma or neuroendocrine tumor
  • Known hypersensitivity for MRI contrast
  • Pacemaker or prosthesis with incompatibility for MRI
  • Claustrophobia
  • Pregnancy or breastfeeding
  • Not able to understand nature of the study procedure
  • Performance status ECOG score: \>2

Key Trial Info

Start Date :

December 12 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2028

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT05298722

Start Date

December 12 2022

End Date

March 1 2028

Last Update

April 2 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Ghent University Hospital

Ghent, East Flanders, Belgium, 9000

2

AZ Sint Blasius Dendermonde

Dendermonde, Belgium, 9200

3

AZ Alma Eeklo

Eeklo, Belgium, 9900

4

AZ Jan Palfijn Ghent

Ghent, Belgium, 9000

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial) | DecenTrialz